Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Humana and Aledade Announce 10 Year Collaboration: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and Aledade Announce 10 Year Collaboration


Aledade, the nation’s largest network of independent primary care, and Humana Inc. (NYSE: HUM), leading health insurer and health care services company, have announced a 10-year collaboration to

Vistagen to Present at Cowen 43rd Annual Health Care Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Cowen 43rd Annual Health Care Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France


Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in

Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD): https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Regulatory News:



POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate

Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen’s 43rd

Agilent Reports First-Quarter Fiscal Year 2023 Financial Results:
Agilent Reports First-Quarter Fiscal Year 2023 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.76 billion for the first quarter ended January 31, 2023, an increase of 5% compared to the first quarter of 2022 and up 10% on a

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.



On February 24

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and the full year ended December 31, 2022. Amounts are expressed in

ICON plc to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to Present at Upcoming Investor Conferences


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi

Acadia Healthcare Reports Fourth Quarter 2022 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Fourth Quarter 2022 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2022.



Fourth Quarter Highlights




  • Revenue totaled $675.3

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical

Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler


Agilent Technologies Inc. (NYSE: A) today announced the release of an on-deck thermal cycler (ODTC) that integrates with the Agilent Bravo NGS automated liquid handling platform. The optional ODTC

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming

Inogen Announces Fourth Quarter and Full Year 2022 Financial Results: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces Fourth Quarter and Full Year 2022 Financial Results


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the

Inogen to Provide Strategy Update on February 27, 2023: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Provide Strategy Update on February 27, 2023


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will host a conference call on Monday

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

EQS-News: Abivax publishes a prospectus in the context of its capital increase
EQS-News: Abivax publishes a prospectus in the context of its capital increase
EQS-News: Abivax publishes a prospectus in the context of its capital increase